Caxton Associates LLP Invests $2.76 Million in Abivax SA Sponsored ADR $ABVX

Caxton Associates LLP purchased a new stake in Abivax SA Sponsored ADR (NASDAQ:ABVX) in the 1st quarter, according to the company in its most recent 13F filing with the SEC. The fund purchased 24,750 shares of the company’s stock, valued at approximately $2,756,000.

A number of other institutional investors and hedge funds also recently modified their holdings of ABVX. Nan Fung Trinity HK Ltd. lifted its stake in shares of Abivax by 11.8% in the 4th quarter. Nan Fung Trinity HK Ltd. now owns 113,365 shares of the company’s stock valued at $15,288,000 after purchasing an additional 12,000 shares in the last quarter. Total Clarity Wealth Management Inc. acquired a new stake in Abivax during the 4th quarter worth approximately $1,247,000. Tudor Investment Corp ET AL purchased a new position in Abivax in the third quarter valued at approximately $2,792,000. Brummer Multi Strategy AB purchased a new position in Abivax in the fourth quarter valued at approximately $1,939,000. Finally, Harbor Capital Advisors Inc. acquired a new position in Abivax during the fourth quarter valued at approximately $1,193,000. Institutional investors and hedge funds own 47.91% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts have issued reports on the stock. Wedbush boosted their price objective on shares of Abivax from $90.00 to $110.00 and gave the stock a “neutral” rating in a research note on Tuesday, June 30th. BTIG Research lifted their target price on shares of Abivax from $150.00 to $175.00 and gave the company a “buy” rating in a report on Tuesday, June 30th. HC Wainwright reaffirmed a “buy” rating on shares of Abivax in a research report on Tuesday, June 30th. Morgan Stanley reiterated an “overweight” rating and issued a $180.00 price target on shares of Abivax in a report on Friday. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Abivax in a research report on Friday, July 17th. Thirteen investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $156.50.

Abivax Price Performance

Shares of ABVX stock opened at $125.70 on Friday. The firm has a fifty day moving average of $117.99 and a two-hundred day moving average of $118.26. The firm has a market cap of $10.96 billion, a P/E ratio of -24.13 and a beta of 0.87. Abivax SA Sponsored ADR has a 1-year low of $65.67 and a 1-year high of $148.83.

Abivax (NASDAQ:ABVX) last issued its quarterly earnings results on Friday, May 22nd. The company reported ($0.71) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.94) by $0.23. The firm had revenue of $1.56 million during the quarter, compared to the consensus estimate of $0.40 million. On average, sell-side analysts expect that Abivax SA Sponsored ADR will post -3.4 EPS for the current year.

Abivax Company Profile

Founded in 2013 and headquartered in Paris, France, Abivax is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for chronic inflammatory diseases and viral infections. The company’s technology platform targets host RNA biogenesis to modulate key immune pathways, offering a differentiated approach aimed at disease modification and improved safety profiles.

Abivax’s lead clinical asset, obefazimod (ABX464), is being evaluated in ulcerative colitis and other inflammatory disorders.